Assembly Biosciences (ASMB) Amortization of Deferred Charges (2010 - 2011)
Assembly Biosciences (ASMB) posted quarterly Amortization of Deferred Charges of $279933.0 for Q3 2011, down 70.01% year-over-year from $933412.0 in Q3 2010, and up 1306.06% quarter-over-quarter from $19909.0 in Q4 2010.
Powered by 
Analysis
Assembly Biosciences (ASMB) Amortization of Deferred Charges (2010 - 2011) Analysis & Trends
Assembly Biosciences' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $279933.0 for Q3 2011.
- In Q3 2011, Amortization of Deferred Charges fell 70.01% year-over-year to $279933.0; the TTM figure through Jun 2012 stood at $279933.0 (changed N/A YoY), while the FY2011 annual figure was $328958.0, down 85.86% from the prior year.
- Amortization of Deferred Charges for Q3 2011 stood at $279933.0, up from $19909.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $933412.0 in Q3 2010, with the low at $19909.0 in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Assembly Biosciences | 683.92 Mn | 363.56 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2011 | 279,933.00 |
| Dec 31, 2010 | 19,909.00 |
| Sep 30, 2010 | 933,412.00 |